Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−92.93 M USD
113.45 M USD
23.63 M
About Gyre Therapeutics, Inc.
Gyre Therapeutics, Inc. operates as a biopharmaceutical company. It is focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis). The firm operates through the BC and Gyre segments. The company was founded on March 7, 1997 and is headquartered in San Diego, CA.
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
The current price of GYRE is 14.67 USD — it has decreased by −3.77% in the past 24 hours. Watch Gyre Therapeutics, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Gyre Therapeutics, Inc. stocks are traded under the ticker GYRE.
GYRE stock has risen by 3.01% compared to the previous week, the month change is a 13.32% rise, over the last year Gyre Therapeutics, Inc. has showed a 53.24% increase.
GYRE reached its all-time high on Mar 1, 2011 with the price of 47,927.89 USD, and its all-time low was 2.83 USD and was reached on Mar 20, 2023. View more price dynamics on GYRE chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
GYRE stock is 3.79% volatile and has beta coefficient of 3.45. Track Gyre Therapeutics, Inc. stock price on the chart and check out the list of the most volatile stocks — is Gyre Therapeutics, Inc. there?
Today Gyre Therapeutics, Inc. has the market capitalization of 1.41 B, it has increased by 4.47% over the last week.
Yes, you can track Gyre Therapeutics, Inc. financials in yearly and quarterly reports right on TradingView.
Gyre Therapeutics, Inc. is going to release the next earnings report on Nov 11, 2024. Keep track of upcoming events with our Earnings Calendar.
GYRE net income for the last quarter is 3.53 M USD, while the quarter before that showed 7.53 M USD of net income which accounts for −53.16% change. Track more Gyre Therapeutics, Inc. financial stats to get the full picture.
As of Nov 8, 2024, the company has 4.00 employees. See our rating of the largest employees — is Gyre Therapeutics, Inc. on this list?
Like other stocks, GYRE shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Gyre Therapeutics, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Gyre Therapeutics, Inc. technincal analysis shows the buy rating today, and its 1 week rating is buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Gyre Therapeutics, Inc. stock shows the neutral signal. See more of Gyre Therapeutics, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.